Philosophy, Psychiatry, & Psychology
September 1, 1996
Dan Lloyd
1 citation
Commentary on “Searle and the ‘Deep Unconscious’” Dan Lloyd (bio) Can another person know my thoughts with better authority than I know them myself? With his affirmative answer to this question, Freud invented the twentieth-century human, a being whose mind is accessible to scrutiny from outside, and whose attempts at conscious self-explanation are at best partial and in many cases wrong. Even...
Neuroscience
September 1996
T Obradovic, K M Imel, S R White
Methylenedioxymethamphetamine (MDMA) is a mood-altering, legally restricted drug that has been reported to inhibit glutamate-evoked firing of cells in the nucleus accumbens. This study used extracellular recording combined with microiontophoresis to examine whether the inhibitory effect of MDMA on neuronal firing in the nucleus accumbens is mediated by serotonin and/or dopamine. Serotonin and...
Psychopharmacology
September 1, 1996
J K Staley, Q Ouyang, John Pablo et al.
82 citations
The purported efficacy of ibogaine for the treatment of drug dependence may be due in part to an active metabolite. Ibogaine undergoes first pass metabolism and is O-demethylated to 12-hydroxyibogamine (12-OH ibogamine). Radioligand binding assays were conducted to identify the potency and selectivity profiles for ibogaine and 12-OH ibogamine. A comparison of 12-OH ibogamine to the primary...
Brain Research
August 26, 1996
R A Rabin, Jerrold C Winter
7 citations
The effects of the antiaddictive compound, ibogaine, and its primary metabolite, noribogaine (12-hydroxyibogamine), on phosphoinositide hydrolysis were investigated. Although ibogaine did not alter phosphoinositide turnover in either striatal or hippocampal slices, noribogaine elicited a concentration-dependent increase in the generation of [3H]inositol phosphates. This stimulation was not...
European Journal of Pharmacology
August 8, 1996
Richard T. Layer, Phil Skolnick, C M Bertha et al.
48 citations
Based on both preclinical findings and anecdotal evidence in man, the psychoactive indole alkaloid ibogaine has been suggested to have anti-addictive properties. Previous studies indicate that blockade of NMDA receptors may mediate at least some of the putative anti-addictive actions of ibogaine. The potencies of a series of ibogaine analogs to inhibit...
Synapse
August 1996
X M Gao, Carol A. Tamminga
Phencyclidine (PCP) is a psychotomimetic drug associated with acute and delayed mental effects in normal humans and psychosis exacerbation in already psychotic schizophrenic individuals. We have previously described a dose-sensitive, delayed action of PCP on regional cerebral metabolism in the rat which occurs over 48 hours and a late (24 hour) change in N-methyl-d-aspartate (NMDA) and kainate...
Neuropsychopharmacology
August 1996
J H Kehne, H J Ketteler, T C McCloskey et al.
(+/-)3,4-Methylenedioxymethamphetamine (MDMA) releases dopamine and serotonin in vivo and stimulates locomotor activity. Previous work demonstrated that MDMA-stimulated dopamine release could be reduced by the selective 5-HT2A receptor antagonist [R-(+)-a- (2,3-dimethoxyphenyl)-1-[2-(4-fluorophenylethyl)]-4-piperidinem ethanol] (MDL 100,907). In the present study MDL 100,907 significantly...
Psychopharmacology
July 1996
Aron H Lichtman, B R Martin
The purpose of the present study was to investigate whether the cannabinoid and cholinergic systems impair working memory through a common mechanism. This hypothesis was tested by examining whether the cannabinoid antagonist SR141716A would ameliorate radial-arm performance deficits caused by either the naturally occurring cannabinoid, delta 9-THC, or scopolamine, a muscarinic antagonist. In...
Progress in Neuro-Psychopharmacology and Biological Psychiatry
July 1, 1996
Tracey Luxton, Linda A. Parker, S Siegel
13 citations
1. Ibogaine, a proposed anti-addictive agent, has been found to interfere with the acquisition of a weak morphine-induced place preference. The present series of experiments determined if ibogaine would interfere with the expression of a previously established morphine (5 mg/kg) place preference. 2. A single injection of 40 mg/kg of ibogaine 24 h, 12 h or 4 h prior to the preference test...
Alcoholism Treatment Quarterly
June 14, 1996
David Rioux
10 citations
This article constitutes an introduction to shamanic healing techniques as promoters of a holistic addiction counseling process. It describes the shaman as one who, by entering an altered state of consciousness, focuses on inner realities in order to find healing, harmony, wholeness for self and others. It pormays healing (i.e., Recovery from addiction) as a transformation of consciousness. It...